AKTX

Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics PLC (AKTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C-
Factor Score 2.1 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.1
Rev Growth YoY 0.0%
Gross Margin N/A
Price Return 3M 30.1%
Price Return 12M -80.7%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 478.4K
ROE -155.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C- (2.1) C (2.3) C+ (2.7) C (2.4) C- (1.9) C (2.3)
2026-08-04 C- (2.1) C (2.3) C+ (2.7) C (2.4) C- (1.9) C (2.3)
2026-08-03 C- (2.1) C (2.4) C- (2.0) C (2.4) C- (2.0) C (2.2)
2026-08-02 C- (2.1) C (2.4) C- (2.0) C (2.4) C- (1.9) C (2.2)